Duygu Ersozlu

Adana, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database.

The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database.

Journal: European journal of rheumatology

Published: January 18, 2023

Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?

Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?

Journal: Rheumatology international

Published: January 09, 2022

Clinical and laboratory factors associated with bamboo spine in patients with axial spondyloarthritis: are there clues for bamboo spine?

Clinical and laboratory factors associated with bamboo spine in patients with axial spondyloarthritis: are there clues for bamboo spine?

Journal: Clinical and experimental rheumatology

Published: December 04, 2021

Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study.

Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study.

Journal: Rheumatology advances in practice

Published: November 10, 2021

Pregnancy in Takayasu's arteritis has a high risk of hypertension-related fetomaternal complications: A retrospective study of a Turkish cohort.

Pregnancy in Takayasu's arteritis has a high risk of hypertension-related fetomaternal complications: A retrospective study of a Turkish cohort.

Journal: International journal of rheumatic diseases

Published: June 30, 2021

In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?

In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?

Journal: Rheumatology international

Published: May 03, 2021

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Journal: Turkish journal of medical sciences

Published: December 01, 2020

Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results.

Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results.

Journal: American journal of ophthalmology

Published: October 22, 2020

Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.

Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.

Journal: Clinical and experimental rheumatology

Published: March 28, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026